BTMD biote Corp.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: hormone optimization training and Biote-branded dietary supplements sold to Biote-certified practitioners and partnered clinics
• • Strategic emphasis on managing risks related to outsourcing facilities that compound bioidentical hormones, including recent acquisition of Asteria Health (Mar 2024)

Risk Factors

• • Regulatory risk from potential liability and recalls linked to compounded drug formulations via outsourcing facilities, posing reputational harm
• • Macroeconomic exposure from 2.5% revenue decline to $192.2M in 2025 due to slowdown in new clinic additions and procedure volumes

Management Discussion & Analysis

• • No quarterly revenue or YoY change data disclosed in MD&A
• • No profitability or margin figures reported for the quarter or YoY comparisons

Risk Factors

• • New risk: Share repurchase program authorized up to $20.0M, with $11.0M remaining as of Sept 30, 2025, introducing potential stock price volatility
• • Material update: Rising tariffs on estradiol from China and trocars from Pakistan increasing raw material costs and supply chain risks

What are the latest BTMD SEC filings in 2026?

biote Corp. (BTMD) has filed a 10-K annual report on March 13, 2026, a 10-Q quarterly report on November 7, 2025, an 8-K current report on April 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did BTMD file its most recent 10-K annual report?

biote Corp. (BTMD) filed its most recent 10-K annual report on March 13, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view BTMD 10-Q quarterly reports?

biote Corp. (BTMD)'s most recent 10-Q quarterly report was filed on November 7, 2025. SignalX displays every BTMD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has BTMD filed recently?

biote Corp. (BTMD)'s most recent 8-K was filed on April 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find BTMD insider trading activity (Form 4)?

SignalX aggregates every BTMD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does BTMD file with the SEC?

biote Corp. (BTMD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BTMD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for biote Corp. (BTMD).

What is BTMD's SEC CIK number?

biote Corp. (BTMD)'s SEC CIK (Central Index Key) number is 1819253. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1819253 to look up all BTMD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find BTMD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from biote Corp. (BTMD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.